The human Eb- and Ec-domains contain the 16 common aa and 61 and 24 additional isoform-specific aa respectively, with a predicted molecular weight of 16.5 kDa for proIGF-1Eb and 12.5 kDa for proIGF-1Ec
Select your peptide, enter vial size and BAC water volume, and get precise ml and IU values
Adding too much water simply results in a more diluted solution
Studies research the involvement of BPC-157 and TB-500 in soft tissue repair, angiogenesis (the process by which the body grows new blood vessels from existing ones), and cellular migration
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
It is important to adhere to the advised dosages to prevent these potential side effects